Volume 19, Issue 11 e202200660
Research Article

New Jatrophane-Type Diterpenoids from Euphorbia kansui as Potential MDR Reversal Agents

Qiong Zheng

Qiong Zheng

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014 P. R. China

Search for more papers by this author
Ning-Yu Chen

Ning-Yu Chen

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014 P. R. China

Search for more papers by this author
Si-Qing Lou

Si-Qing Lou

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014 P. R. China

Search for more papers by this author
Qian-Qing Liu

Qian-Qing Liu

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014 P. R. China

Search for more papers by this author
Yi-Tong Luo

Yi-Tong Luo

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014 P. R. China

Search for more papers by this author
Dong-E Liang

Dong-E Liang

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014 P. R. China

Search for more papers by this author
Zha-Jun Zhan

Zha-Jun Zhan

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014 P. R. China

Search for more papers by this author
Lie-Feng Ma

Corresponding Author

Lie-Feng Ma

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014 P. R. China

Search for more papers by this author
First published: 25 September 2022

Abstract

A serial jatrophane-type diterpenoids, comprised with three undescribed compounds kanesulones C−E (13) and four known ones (47), were obtained from the roots of Euphorbia kansui. The structures of compounds 13 were elucidated by detailed interpretation of their spectroscopic data, especially 2D-NMR and HR-ESI-MS, the absolute configuration of 1 was revealed by single crystal X-ray diffraction. These isolates were assayed for their multidrug resistance reversing activities on human breast adenocarcinoma cell line MCF-7/ADR. Compound 1 possessed potential as low toxic MDR modulator that could promote the efficacy of anticancer drug adriamycin ca. 85-fold at 5 μM, as 12 times stronger than the positive drug verapamil.

Graphical Abstract

Conflict of interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.